Condition: Anxiety Disorders · Anxiety · Depression · Sponsor: University of California, San Diego
This study seeks to understand if the medication pramipexole improves social connectedness and functioning in adults (ages 18-50) who experience anxiety or depression. The study plans to enroll 108 participants total across two sites (University of California San Diego and New York State Psychiatric Institute). Pramipexole will be given in a 6-week randomized, double-blind, placebo-controlled trial. Social reward processing will be assessed using measures of brain function (fMRI), behavior, and self-report at baseline and week 6. Knowledge gained from this study will help determine the therapeutic potential of targeting the dopamine system to remediate social disconnection as an anxiety and depression intervention.
This description comes directly from the study's public registry record.
Nuzhat Beg, MBBS, MAS · 858-534-6436 · nbeg@health.ucsd.edu
Taylor Smith, B.S. · trs004@health.ucsd.edu
Always discuss trial participation with your own doctor first.
| University of California, San Diego | San Diego, California, United States | Recruiting |
| New York State Psychiatric Institute | New York, New York, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06269146